For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024 Debates and Didactics in Hematology and Oncology conference by two myeloma experts from Emory University Winship Cancer Center,¹ which sponsors the annual event. Ajay K. Nooka, MD, MPH, Professor and Director of the Myeloma Program, and Nisha S. Joseph, MD, Associate Professor, both of the Department of Hematology and Medical Oncology at Emory, reviewed the data from pivotal trials that may inform clinicians in their treatment selection.

With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission.

The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of lymph node–only metastases (ie, cN+ urothelial cancer), providing optimism that patients with this type of urothelial carcinoma may achieve long-term remission. These findings were based on a post hoc subset analysis of the phase III CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.

In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard radiotherapy in patients with inoperable stage III non–small cell lung cancer (NSCLC).